Furthermore, upon combination treatment with CCR2 antagonist and the immune checkpoint inhibitor PD-1 antibody, suppression of tumor growth was found to be more effective compared with the PD-1 antibody alone. The gene discussed is CCR2; the disease is neoplasm.